We are pleased to announce key appointments to our Scientific Advisory Board, with both new members strategically selected to help support our growth strategy.
j.yeh15 December 2021
We are excited to announnce that Joshua Young will join our leadership team to lead the company’s Investor Relations, Communications and Strategy functions.
j.yeh27 October 2021
We are pleased to announce two key appointments to our Board of Directors that bring a combined 40 years of executive-level experience in human resources and finance. Melissa McLaughlin and Solange Glaize are the newest addition to LUMICKS Board, each offering invaluable insight that will help pave the way for…
j.yeh30 September 2021
We are pleased to announce the appointment of Dr. Paul Wheeler to its leadership team, effective July 1, 2021. In the newly-created position of Chief Commercial Officer, Dr. Wheeler will lead LUMICKS aggressive commercial growth strategy by building a stronger market presence, developing highly-effective sales teams, and focusing on enhanced…
j.yeh17 August 2021
We're proud to announce ithe installation of a C-Trap® Optical Tweezers – Fluorescence & Label-free Microscopy system at VIB, the life sciences research institute in Flanders, Belgium. The C-Trap will support the research efforts of six VIB research groups across three Belgian universities studying processes underlying neurodegenerative disorders.
j.yeh28 July 2021
INmune Bio is employing the z-Movi® cell avidity analysis platform to demonstrate that the mechanism of action of the tumor-priming is the increase in NK cell:tumor cell avidity. Early data acquired by the z-Movi® support their hypothesis that increased cell avidity enhances NK cell killing of tumor cells. This allows…
j.yeh22 July 2021
In 2019, LUMICKS employees flew across the world to connect and collaborate with customers. To combat the unavoidable emissions their travel generated, the company sponsored the planting of 5,500 trees on former farmland. Over the next 30 years, those trees are expected to capture 1-1.5 times the CO2 emissions of…
j.yeh16 June 2021
In its effort to develop effective cellular immunotherapies for cancer treatment, the Regensburg Center for Interventional Immunology (RCI) in Germany has purchased LUMICKS’ z-Movi®. The placement highlights the promise of measuring cell avidity between immune cells and their tumor targets to improve the selection of CARs and accelerate the development…
j.yeh26 May 2021
LUMICKS, a leading next generation life science tools company renowned for its innovative platforms for Dynamic Single-Molecule and Cell Avidity analysis, announces that it has made the decision to return the COVID-related relief funding it received in both the Netherlands and the United States. During 2020, LUMICKS received a total…
j.yeh18 May 2021
